{
 "disease": "uveal-melanoma",
 "label": "Uveal melanoma",
 "url": "https://usebiotransfer.org/disease/uveal-melanoma/",
 "built": "2026-09-17",
 "facts_hash": {
  "answers": "a28f5b368421",
  "targets": "0dcd994ca3d3"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-17",
  "trials": "2026-09-17"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "GNAQ",
   "ensembl": "ENSG00000156052",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "GNA11",
   "ensembl": "ENSG00000088256",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "BAP1",
   "ensembl": "ENSG00000163930",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "SF3B1",
   "ensembl": "ENSG00000115524",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "EIF1AX",
   "ensembl": "ENSG00000173674",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "CYSLTR2",
   "ensembl": "ENSG00000152207",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "PLCB4",
   "ensembl": "ENSG00000101333",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "PMEL",
   "ensembl": "ENSG00000185664",
   "n_drug_entries": 2,
   "n_distinct_drugs": 2,
   "drugs": {
    "IMC-GP100": "EARLY_PHASE_1",
    "TEBENTAFUSP": "APPROVAL"
   },
   "approved": [
    "TEBENTAFUSP"
   ],
   "n_approved": 1,
   "approved_for": {
    "TEBENTAFUSP": [
     "gastric cancer",
     "uveal cancer",
     "melanoma"
    ]
   },
   "tractability": [
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "MET",
   "ensembl": "ENSG00000105976",
   "n_drug_entries": 38,
   "n_distinct_drugs": 36,
   "drugs": {
    "ALTIRATINIB": "PHASE_1",
    "AMG-208": "PHASE_2",
    "AMG-337": "PHASE_2",
    "AMIVANTAMAB": "APPROVAL",
    "AMUVATINIB": "PHASE_2",
    "ARRY-300": "PHASE_1",
    "BAFISONTAMAB": "PHASE_2",
    "BEPERMINOGENE PERPLASMID": "PHASE_3",
    "BMS-777607": "PHASE_1_2",
    "BMS-817378": "PHASE_1",
    "BPI-9016": "PHASE_1",
    "CABOZANTINIB": "APPROVAL",
    "CABOZANTINIB S-MALATE": "APPROVAL",
    "CAPMATINIB": "APPROVAL",
    "CRIZOTINIB": "APPROVAL",
    "EMD-1204831": "PHASE_1",
    "EMIBETUZUMAB": "PHASE_2",
    "FORETINIB": "PHASE_2",
    "GLESATINIB": "PHASE_2",
    "GOLVATINIB": "PHASE_1_2",
    "JNJ-38877605": "PHASE_1",
    "MERESTINIB": "PHASE_2",
    "MK-2461": "PHASE_1_2",
    "MK-8033": "PHASE_1",
    "NINGETINIB": "PHASE_2",
    "ONARTUZUMAB": "PHASE_3",
    "PF-04217903": "PHASE_1",
    "SAR-125844": "PHASE_2",
    "SAVOLITINIB": "PHASE_3",
    "SGX-523": "PHASE_1",
    "TAS-115": "PHASE_1",
    "TELISOTUZUMAB": "PHASE_1",
    "TELISOTUZUMAB VEDOTIN": "PHASE_3",
    "TEPOTINIB": "APPROVAL",
    "TEREVALEFIM": "PHASE_3",
    "TIVANTINIB": "PHASE_3"
   },
   "approved": [
    "AMIVANTAMAB",
    "CABOZANTINIB",
    "CABOZANTINIB S-MALATE",
    "CAPMATINIB",
    "CRIZOTINIB",
    "TEPOTINIB"
   ],
   "n_approved": 6,
   "approved_for": {
    "AMIVANTAMAB": [
     "non-small cell lung carcinoma"
    ],
    "CABOZANTINIB": [
     "thyroid cancer",
     "thyroid tumor",
     "hepatocellular carcinoma",
     "renal cell carcinoma",
     "medullary thyroid gland carcinoma"
    ],
    "CABOZANTINIB S-MALATE": [
     "thyroid gland carcinoma",
     "renal cell carcinoma"
    ],
    "CAPMATINIB": [
     "non-small cell lung carcinoma"
    ],
    "CRIZOTINIB": [
     "non-small cell lung carcinoma"
    ],
    "TEPOTINIB": [
     "non-small cell lung carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "MITF",
   "ensembl": "ENSG00000187098",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "PRKCA",
   "ensembl": "ENSG00000154229",
   "n_drug_entries": 6,
   "n_distinct_drugs": 6,
   "drugs": {
    "APRINOCARSEN": "PHASE_3",
    "CEP-2563": "PHASE_1",
    "GSK-690693": "PHASE_1",
    "MIDOSTAURIN": "APPROVAL",
    "SOTRASTAURIN": "PHASE_2",
    "UCN-01": "PHASE_2"
   },
   "approved": [
    "MIDOSTAURIN"
   ],
   "n_approved": 1,
   "approved_for": {
    "MIDOSTAURIN": [
     "mast cell leukemia",
     "mastocytosis",
     "acute myeloid leukemia by FAB classification",
     "systemic mastocytosis",
     "acute myeloid leukemia"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "MBD4",
   "ensembl": "ENSG00000129071",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "gp100": {
    "n": 32,
    "n_observational": 1,
    "n_active": 12,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06070012",
      "title": "Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06246149",
      "title": "Adjuvant Tebentafusp in High Risk Ocular Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06414590",
      "title": "Neoadjuvant Tebentafusp for Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06626516",
      "title": "Tebentafusp-tebn With LDT in Metastatic UM",
      "status": "RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06627244",
      "title": "Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07057596",
      "title": "Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07063875",
      "title": "Adding IL-2 to Tebentafusp to Eradicate Cancer Progression",
      "status": "RECRUITING",
      "last_update": "2025-07-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07203391",
      "title": "Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis",
      "status": "RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07276386",
      "title": "Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003339",
      "title": "Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005841",
      "title": "Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma",
      "status": "TERMINATED",
      "last_update": "2014-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00020475",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye",
      "status": "COMPLETED",
      "last_update": "2024-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00025181",
      "title": "Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery",
      "status": "COMPLETED",
      "last_update": "2014-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00031733",
      "title": "Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00032045",
      "title": "Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00036816",
      "title": "Vaccine Therapy in Treating Patients With Melanoma of the Eye",
      "status": "TERMINATED",
      "last_update": "2012-09-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00084656",
      "title": "Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-04-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00085189",
      "title": "Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00089063",
      "title": "Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00254397",
      "title": "Melanoma Vaccine With Peptides and Leuprolide",
      "status": "COMPLETED",
      "last_update": "2019-10-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00313508",
      "title": "Dendritic Cell Vaccination During Lymphoid Reconstruction",
      "status": "COMPLETED",
      "last_update": "2014-02-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00334776",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2014-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00398073",
      "title": "Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-03-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00471471",
      "title": "Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2017-06-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00929019",
      "title": "Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients",
      "status": "TERMINATED",
      "last_update": "2018-12-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01989572",
      "title": "Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2026-06-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02570308",
      "title": "A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-03-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02889861",
      "title": "IMCgp100-401 Rollover Study",
      "status": "TERMINATED",
      "last_update": "2020-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03070392",
      "title": "Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05315258",
      "title": "Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05415072",
      "title": "A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07803562",
      "title": "Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "gp100",
     "tebentafusp",
     "Kimmtrak",
     "IMCgp100",
     "PMEL"
    ]
   },
   "PD-1": {
    "n": 45,
    "n_observational": 2,
    "n_active": 18,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT03686124",
      "title": "ACTengine\u00ae IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04855435",
      "title": "Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06022029",
      "title": "A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.",
      "status": "RECRUITING",
      "last_update": "2025-12-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06121180",
      "title": "Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2025-12-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06413680",
      "title": "A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body",
      "status": "RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06519266",
      "title": "PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases",
      "status": "RECRUITING",
      "last_update": "2024-11-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06581406",
      "title": "A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Na\u00efve Adult Patients With Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07501117",
      "title": "Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01585194",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02346955",
      "title": "Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)",
      "status": "TERMINATED",
      "last_update": "2020-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02359851",
      "title": "Pembrolizumab in Treating Patients With Advanced Uveal Melanoma",
      "status": "TERMINATED",
      "last_update": "2019-09-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02519322",
      "title": "Neoadjuvant and Adjuvant Checkpoint Blockade",
      "status": "COMPLETED",
      "last_update": "2024-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02626962",
      "title": "Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-03-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02697630",
      "title": "Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye",
      "status": "COMPLETED",
      "last_update": "2023-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02831933",
      "title": "Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02858869",
      "title": "Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases",
      "status": "COMPLETED",
      "last_update": "2026-03-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02913417",
      "title": "Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases",
      "status": "UNKNOWN",
      "last_update": "2021-04-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03006887",
      "title": "Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2021-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03025256",
      "title": "Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03070392",
      "title": "Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03326258",
      "title": "Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery",
      "status": "WITHDRAWN",
      "last_update": "2018-07-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03472586",
      "title": "Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver",
      "status": "COMPLETED",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03528408",
      "title": "Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-04-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03611868",
      "title": "A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03922880",
      "title": "Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-05-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04130516",
      "title": "Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04283890",
      "title": "PHP and Immunotherapy in Metastasized UM",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04336241",
      "title": "Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04463368",
      "title": "Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases",
      "status": "COMPLETED",
      "last_update": "2025-03-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04552223",
      "title": "Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04802876",
      "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04935229",
      "title": "Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma",
      "status": "TERMINATED",
      "last_update": "2025-10-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04993677",
      "title": "A Study of SEA-CD40 Given With Other Drugs in Cancers",
      "status": "COMPLETED",
      "last_update": "2025-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05004025",
      "title": "Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05077280",
      "title": "A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma",
      "status": "UNKNOWN",
      "last_update": "2022-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05169957",
      "title": "Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)",
      "status": "COMPLETED",
      "last_update": "2024-11-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05282901",
      "title": "Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)",
      "status": "COMPLETED",
      "last_update": "2026-07-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05308901",
      "title": "Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Na\u00efve Metastatic Uveal Melanoma",
      "status": "TERMINATED",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05341349",
      "title": "Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases",
      "status": "TERMINATED",
      "last_update": "2026-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05524935",
      "title": "Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05576077",
      "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05585034",
      "title": "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb\u00ae808 in Combination With Pembrolizumab in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-08-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05640193",
      "title": "A Study of LN-144 in People With Metastatic Melanoma to the Brain",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05987332",
      "title": "IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06784648",
      "title": "Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "PD-1",
     "nivolumab",
     "pembrolizumab"
    ]
   },
   "CTLA-4": {
    "n": 30,
    "n_observational": 0,
    "n_active": 6,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT06519266",
      "title": "PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases",
      "status": "RECRUITING",
      "last_update": "2024-11-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06581406",
      "title": "A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Na\u00efve Adult Patients With Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07501117",
      "title": "Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00025181",
      "title": "Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery",
      "status": "COMPLETED",
      "last_update": "2014-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00032045",
      "title": "Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00058279",
      "title": "Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2013-06-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00084656",
      "title": "Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-04-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01355120",
      "title": "THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease",
      "status": "COMPLETED",
      "last_update": "2025-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01585194",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2024-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01730157",
      "title": "Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases",
      "status": "TERMINATED",
      "last_update": "2016-03-10",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02158520",
      "title": "Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2020-01-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02519322",
      "title": "Neoadjuvant and Adjuvant Checkpoint Blockade",
      "status": "COMPLETED",
      "last_update": "2024-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02626962",
      "title": "Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2022-03-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02913417",
      "title": "Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases",
      "status": "UNKNOWN",
      "last_update": "2021-04-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03068624",
      "title": "Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma",
      "status": "UNKNOWN",
      "last_update": "2024-01-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03070392",
      "title": "Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03326258",
      "title": "Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery",
      "status": "WITHDRAWN",
      "last_update": "2018-07-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03408587",
      "title": "CAVATAK\u00ae and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)",
      "status": "COMPLETED",
      "last_update": "2023-05-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03472586",
      "title": "Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver",
      "status": "COMPLETED",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03528408",
      "title": "Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma",
      "status": "UNKNOWN",
      "last_update": "2023-04-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03752398",
      "title": "A Study of XmAb\u00ae23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)",
      "status": "COMPLETED",
      "last_update": "2024-07-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03922880",
      "title": "Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-05-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04283890",
      "title": "PHP and Immunotherapy in Metastasized UM",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04463368",
      "title": "Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases",
      "status": "COMPLETED",
      "last_update": "2025-03-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04935229",
      "title": "Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma",
      "status": "TERMINATED",
      "last_update": "2025-10-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05004025",
      "title": "Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2025-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05169957",
      "title": "Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)",
      "status": "COMPLETED",
      "last_update": "2024-11-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05341349",
      "title": "Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases",
      "status": "TERMINATED",
      "last_update": "2026-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05987332",
      "title": "IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06784648",
      "title": "Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 1,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT03068624",
       "title": "Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma",
       "status": "UNKNOWN",
       "last_update": "2024-01-25",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CTLA-4",
     "ipilimumab"
    ]
   },
   "PKC": {
    "n": 11,
    "n_observational": 0,
    "n_active": 6,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03947385",
      "title": "Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions",
      "status": "RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07015190",
      "title": "Neoadjuvant Darovasertib in Primary Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-05-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07804186",
      "title": "Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-09-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01430416",
      "title": "Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2020-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01801358",
      "title": "A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-09-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02273219",
      "title": "Trial of AEB071 in Combination With BYL719 in Patients With Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02601378",
      "title": "A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.",
      "status": "TERMINATED",
      "last_update": "2022-09-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05187884",
      "title": "Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05907954",
      "title": "(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05987332",
      "title": "IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07747935",
      "title": "Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "PKC",
     "darovasertib",
     "LXS196",
     "IDE196",
     "sotrastaurin"
    ]
   },
   "MEK": {
    "n": 10,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT03947385",
      "title": "Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions",
      "status": "RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01143402",
      "title": "Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye",
      "status": "COMPLETED",
      "last_update": "2017-07-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01328106",
      "title": "Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2017-12-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01801358",
      "title": "A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-09-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01974752",
      "title": "Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)",
      "status": "COMPLETED",
      "last_update": "2017-01-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01979523",
      "title": "Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02768766",
      "title": "Intermittent Selumetinib for Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-08-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04720417",
      "title": "Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma",
      "status": "TERMINATED",
      "last_update": "2025-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05170334",
      "title": "Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05677373",
      "title": "Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2023-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "MEK",
     "selumetinib",
     "trametinib",
     "binimetinib"
    ]
   },
   "cMET": {
    "n": 7,
    "n_observational": 2,
    "n_active": 4,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT03947385",
      "title": "Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions",
      "status": "RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06626516",
      "title": "Tebentafusp-tebn With LDT in Metastatic UM",
      "status": "RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07804186",
      "title": "Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-09-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01835145",
      "title": "Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2022-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02223819",
      "title": "Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy",
      "status": "COMPLETED",
      "last_update": "2023-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03022565",
      "title": "Vorinostat in Patients With Class 2 High Risk Uveal Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2020-02-06",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05987332",
      "title": "IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "MET",
     "crizotinib",
     "cabozantinib"
    ]
   },
   "liver-directed": {
    "n": 20,
    "n_observational": 1,
    "n_active": 9,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06519266",
      "title": "PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases",
      "status": "RECRUITING",
      "last_update": "2024-11-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06627244",
      "title": "Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07276386",
      "title": "Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07364474",
      "title": "Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver",
      "status": "RECRUITING",
      "last_update": "2026-03-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00062933",
      "title": "A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma",
      "status": "COMPLETED",
      "last_update": "2012-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00096083",
      "title": "Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer",
      "status": "COMPLETED",
      "last_update": "2013-10-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00110123",
      "title": "Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma",
      "status": "TERMINATED",
      "last_update": "2012-09-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00324727",
      "title": "Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma",
      "status": "COMPLETED",
      "last_update": "2021-06-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01730157",
      "title": "Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases",
      "status": "TERMINATED",
      "last_update": "2016-03-10",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01785316",
      "title": "The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases",
      "status": "COMPLETED",
      "last_update": "2024-01-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01893099",
      "title": "Sorafenib and Radioembolization With Sir-Spheres\u00ae for the Treatment of Metastatic Ocular Melanoma",
      "status": "COMPLETED",
      "last_update": "2018-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02678572",
      "title": "Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-09-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02936388",
      "title": "Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis",
      "status": "COMPLETED",
      "last_update": "2025-01-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04283890",
      "title": "PHP and Immunotherapy in Metastasized UM",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04463368",
      "title": "Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases",
      "status": "COMPLETED",
      "last_update": "2025-03-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04812470",
      "title": "Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases",
      "status": "COMPLETED",
      "last_update": "2025-09-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05022901",
      "title": "An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2023-12-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05893654",
      "title": "Melphalan Chemoreduction for Ocular Melanoma",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2025-09-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05903937",
      "title": "Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07183852",
      "title": "Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 2,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT04812470",
       "title": "Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases",
       "status": "COMPLETED",
       "last_update": "2025-09-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07183852",
       "title": "Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-09-09",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "hepatic perfusion",
     "melphalan",
     "Hepzato",
     "chemosaturation",
     "radioembolization"
    ]
   },
   "LAG-3": {
    "n": 5,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02519322",
      "title": "Neoadjuvant and Adjuvant Checkpoint Blockade",
      "status": "COMPLETED",
      "last_update": "2024-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03538028",
      "title": "A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2020-10-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04552223",
      "title": "Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04935229",
      "title": "Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma",
      "status": "TERMINATED",
      "last_update": "2025-10-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05077280",
      "title": "A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma",
      "status": "UNKNOWN",
      "last_update": "2022-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "LAG-3",
     "relatlimab"
    ]
   },
   "HDAC": {
    "n": 7,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT07136181",
      "title": "Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2025-11-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00020579",
      "title": "MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma",
      "status": "COMPLETED",
      "last_update": "2012-03-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00121225",
      "title": "Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma",
      "status": "COMPLETED",
      "last_update": "2019-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01587352",
      "title": "Vorinostat in Treating Patients With Metastatic Melanoma of the Eye",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02697630",
      "title": "Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye",
      "status": "COMPLETED",
      "last_update": "2023-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02936388",
      "title": "Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis",
      "status": "COMPLETED",
      "last_update": "2025-01-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03022565",
      "title": "Vorinostat in Patients With Class 2 High Risk Uveal Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2020-02-06",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "HDAC",
     "vorinostat",
     "entinostat"
    ]
   }
  },
  "by_drug": {
   "CABOZANTINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01835145",
      "title": "Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2022-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CABOZANTINIB S-MALATE": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01835145",
      "title": "Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2022-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CRIZOTINIB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03947385",
      "title": "Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions",
      "status": "RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07804186",
      "title": "Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-09-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02223819",
      "title": "Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy",
      "status": "COMPLETED",
      "last_update": "2023-12-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05987332",
      "title": "IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SOTRASTAURIN": {
    "n": 4,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01430416",
      "title": "Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients",
      "status": "COMPLETED",
      "last_update": "2020-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01801358",
      "title": "A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma",
      "status": "TERMINATED",
      "last_update": "2020-09-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02273219",
      "title": "Trial of AEB071 in Combination With BYL719 in Patients With Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07747935",
      "title": "Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TEBENTAFUSP": {
    "n": 14,
    "n_observational": 1,
    "n_active": 12,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06070012",
      "title": "Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06246149",
      "title": "Adjuvant Tebentafusp in High Risk Ocular Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06414590",
      "title": "Neoadjuvant Tebentafusp for Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06626516",
      "title": "Tebentafusp-tebn With LDT in Metastatic UM",
      "status": "RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06627244",
      "title": "Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07057596",
      "title": "Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07063875",
      "title": "Adding IL-2 to Tebentafusp to Eradicate Cancer Progression",
      "status": "RECRUITING",
      "last_update": "2025-07-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07203391",
      "title": "Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis",
      "status": "RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07276386",
      "title": "Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02570308",
      "title": "A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2023-03-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03070392",
      "title": "Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma",
      "status": "COMPLETED",
      "last_update": "2026-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05315258",
      "title": "Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05415072",
      "title": "A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07803562",
      "title": "Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}